Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5370613 | 0.87 | KMT2A (0.40) | KMT2AALDH1A1GAALMNAPAX8 | |
| SCHEMBL5359769 | 0.85 | PAX8 (0.37) | KMT2AALDH1A1GAALMNAPAX8 | |
| SCHEMBL5364325 | 0.81 | BRS3 (0.42) | KMT2AALDH1A1GAALMNAPAX8 | |
| SCHEMBL5358308 | 0.80 | PAX8 (0.41) | KMT2AALDH1A1GAALMNAPAX8 | |
| SCHEMBL5378077 | 0.76 | PAX8 (0.36) | ALDH1A1PAX8 | |
| SCHEMBL5368616 | 0.73 | ALDH1A1 (0.56) | KMT2AALDH1A1GAALMNAL3MBTL1 | |
| SCHEMBL5364335 | 0.72 | BRS3 (0.43) | KMT2AALDH1A1GAALMNAPAX8 | |
| SCHEMBL5359143 | 0.71 | ACACA (0.38) | KMT2AALDH1A1GAALMNAL3MBTL1 | |
| SCHEMBL5760505 | 0.68 | ALDH1A1 (0.54) | KMT2AALDH1A1GAALMNAPAX8 | |
| SCHEMBL14578750 | 0.68 | LMNA (0.61) | KMT2AALDH1A1GAALMNAPAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7294716-B2 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | ALLERGAN, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-20050038076-A1 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | ALEVIUM PHARMACEUTICALS, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038076-A1 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | SI, ATP6AP1, HRH2 | KMT2A 1672/4885ALDH1A1 1650/4885GAA 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.